You are here: Industry Insights > Grifols

News List

Grifols Expands Activity in Africa contractpharma
July 28, 2021
Grifols, a global producer of plasma-derived medicines and provider of technologies and services for hospitals, clinics and compounding centers, will establish an intravenous (IV) solutions production plant in Nigeria for Dozie and Dozie's Pharma ...
Singapore’s GIC to invest $1bn in Grifols subsidiary Biomat pharmaceutical-technology
July 02, 2021
The sovereign wealth fund of Singapore, GIC, has agreed to invest approximately $1bn in Biomat, a US-based plasma collection company owned by Grifols.
Grifols to provide Korean Red Cross with Procleix Panther for blood screening, extending donor testing leadership in Asia prnasia
June 03, 2021
Grifols today announced it will provide the Korean Red Cross (KRC) with its industry-leading Procleix Panther System running nucleic acid testing (NAT) technology to help ensure the safety of South Korea's blood supply.
Grifols Begins COVID-19 Plasma Treatment Trial contractpharma
January 19, 2021
Treatment could be used for people who test positive for COVID-19, avoiding hospitalization due to the progression of the disease, complementing the vaccine.
Grifols to Acquire Alkahest for $146M contractpharma
September 18, 2020
Enhances discovery research and development to identify therapies for age-related diseases.
Grifols to acquire biotech company Alkahest for $146m pharmaceutical-technology
September 17, 2020
Spanish plasma therapies developer Grifols has signed an agreement to acquire the remaining stake in US-based biotechnology firm Alkahest for $146m.
Grifols to acquire GC Pharma’s plasma fractionation facility for $460m pharmaceutical-technology
July 22, 2020
Plasma-derived medicines company Grifols has executed purchase arrangements with South Korean-based GC Pharma to acquire a plasma fractionation facility in Montreal, Canada for $460m.
Grifols to Acquire GC Pharma’s Plasma Facilities for $460M contractpharma
July 21, 2020
Gains Montreal-based plasma fractionation facility, two purification facilities, and 11 U.S.-based plasma collection centers.
Grifols Begins Production of Anti-SARS-CoV-2 Hyperimmune Immunoglobulin contractpharma
June 16, 2020
Potential anti-COVID-19 passive immune therapy is part of a collaboration with the U.S. government, first doses for trials are expected July 2020.
Grifols teams up with US to test plasma therapy for Covid-19 pharmaceutical-technology
March 27, 2020
Spanish healthcare company Grifols has teamed up with the US Government agencies, including the Biomedical Advanced Research Development Authority (BARDA) ...

Previous page 1 2 Next page